Quantum BioPharma Ltd. (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to support the Phase 2 clinical trial of Lucid-MS, its investigational drug candidate for progressive multiple sclerosis (MS). The agreement follows the U.S. Food and Drug Administration's clearance of its Investigational New Drug application in August 2026, moving the program toward clinical implementation with a contract research organization experienced in central nervous system and MS studies.
Unlike many existing MS treatments that primarily target the immune system, Lucid-MS is designed to protect myelin, the protective coating around nerve fibers, by inhibiting PAD2, an enzyme implicated in myelin damage. This mechanism could offer a new approach for progressive MS, which currently has limited treatment options. The randomized, double-blind, placebo-controlled trial will evaluate the candidate's safety, tolerability, and efficacy using clinical and radiological measures.
The partnership with Thermo Fisher's clinical research business is significant because it brings specialized expertise in CNS and MS trials, potentially accelerating the timeline and improving trial quality. For Quantum BioPharma, a small biopharmaceutical company, collaborating with a global leader in clinical research adds credibility and resources that are crucial for advancing a novel therapy. The agreement also signals that the company is moving from preclinical and Phase 1 testing into later-stage clinical development, a critical milestone for any drug candidate.
Although preclinical research and Phase 1 testing have provided encouraging findings, Lucid-MS remains investigational, and the company has not yet announced enrollment dates or trial sites. Investors and patients will be watching closely for further updates, as successful Phase 2 results could pave the way for a new class of MS therapies. For more details, see the full article or visit https://ibn.fm/0IAIS.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., focuses on Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also retains ownership in Unbuzzd Wellness Inc. and royalty rights. For more information, visit www.QuantumBioPharma.com. Latest news and updates are available in the company's newsroom at https://ibn.fm/QNTM.
The announcement was distributed via InvestorWire, a specialized communications platform and one of 75+ brands within the Dynamic Brand Portfolio @ IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms, see https://www.InvestorWire.com/Disclaimer.
